Alliance Global Partners analyst James Molloy maintains XORTX Therapeutics (NASDAQ:XRTX) with a Buy and raises the price target from $9 to $14.
Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.